Scholarlink

Purpose <p>Iron deficiency (ID) often leads to iron deficiency anemia (IDA). Oral iron supplements are frequently associated with gastrointestinal intolerance and poor adherence. Ferric derisomaltose (FDI), a single high-dose intravenous (IV) infusion, is another option. The real-world Real-CHOICE study investigated the attitudes of patients with IDA and ID without anemia (IDNA) towards IV iron therapy. Secondary objectives were the effectiveness and safety of FDI.</p> Methods <p>Real-CHOICE (NCT04318405) enrolled adults with IDA or IDNA in Switzerland. Custom questionnaires evaluated attitudes and treatment satisfaction at baseline and follow-up (≥ 12&#xa0;weeks). Hemoglobin, ferritin, and transferrin saturation levels, and treatment-emergent adverse events (TEAEs) were assessed.</p> Results <p>Of 319 patients (114 with IDA, 205 with IDNA) who received FDI, most were female (n = 305, 93.9%) and aged &lt; 65&#xa0;years (n = 298, 91.7%). Over three-quarters of patients were not hesitant to receive IV iron treatment at baseline (n = 228, 76.3%) and follow-up (n = 194, 78.2%). The proportion of patients whose attitude towards receiving IV iron therapy remained stable or improved at follow-up versus baseline was 86.1% (n = 204/237). Of 195 patients with available data, mean (standard deviation) changes from baseline to follow-up in hemoglobin, ferritin, and transferrin saturation levels were 1.15 (1.50) g/dL, 144.87 (131.77) µg/L, and 8.71% (13.29%), respectively. TEAEs and adverse drug reactions occurred in 76 (23.8%) and 22 patients (6.9%), respectively.</p> Conclusion <p>Real-CHOICE revealed favorable attitudes of patients and physicians towards IV iron therapies, particularly FDI, in a real-world setting. Improved hematologic parameters and favorable safety highlight FDI’s potential as a clinically effective treatment for ID and IDA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Attitudes towards ferric derisomaltose among Swiss patients with iron deficiency and their treating physicians: the prospective, observational Real-CHOICE study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月20日

查看全文
  • Petra Stute,
  • Pierre-Alexandre Krayenbühl,
  • Stephan R. Vavricka

摘要

Purpose

Iron deficiency (ID) often leads to iron deficiency anemia (IDA). Oral iron supplements are frequently associated with gastrointestinal intolerance and poor adherence. Ferric derisomaltose (FDI), a single high-dose intravenous (IV) infusion, is another option. The real-world Real-CHOICE study investigated the attitudes of patients with IDA and ID without anemia (IDNA) towards IV iron therapy. Secondary objectives were the effectiveness and safety of FDI.

Methods

Real-CHOICE (NCT04318405) enrolled adults with IDA or IDNA in Switzerland. Custom questionnaires evaluated attitudes and treatment satisfaction at baseline and follow-up (≥ 12 weeks). Hemoglobin, ferritin, and transferrin saturation levels, and treatment-emergent adverse events (TEAEs) were assessed.

Results

Of 319 patients (114 with IDA, 205 with IDNA) who received FDI, most were female (n = 305, 93.9%) and aged < 65 years (n = 298, 91.7%). Over three-quarters of patients were not hesitant to receive IV iron treatment at baseline (n = 228, 76.3%) and follow-up (n = 194, 78.2%). The proportion of patients whose attitude towards receiving IV iron therapy remained stable or improved at follow-up versus baseline was 86.1% (n = 204/237). Of 195 patients with available data, mean (standard deviation) changes from baseline to follow-up in hemoglobin, ferritin, and transferrin saturation levels were 1.15 (1.50) g/dL, 144.87 (131.77) µg/L, and 8.71% (13.29%), respectively. TEAEs and adverse drug reactions occurred in 76 (23.8%) and 22 patients (6.9%), respectively.

Conclusion

Real-CHOICE revealed favorable attitudes of patients and physicians towards IV iron therapies, particularly FDI, in a real-world setting. Improved hematologic parameters and favorable safety highlight FDI’s potential as a clinically effective treatment for ID and IDA.